SCHEMBL20166514

SCHEMBL20166514

N#Cc1cnc(N2CCC(C(=O)N3N=CCC3c3cc(F)ccc3F)CC2)cn1

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 13/20 0.75
TACR3 P29371 6/20 0.46
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20166510 1.00 RIPK1 (0.75) RIPK1TACR3PARP1
SCHEMBL20166338 0.89 RIPK1 (0.75) RIPK1
SCHEMBL20166335 0.89 RIPK1 (0.75) RIPK1
SCHEMBL20182808 0.86 RIPK1 (1.00) RIPK1TACR3PARP1
SCHEMBL21546075 0.86 RIPK1 (1.00) RIPK1TACR3PARP1
SCHEMBL20182772 0.82 RIPK1 (0.75) RIPK1
SCHEMBL21546092 0.82 RIPK1 (0.75) RIPK1
SCHEMBL20168906 0.78 RIPK1 (0.53) RIPK1
SCHEMBL20168907 0.78 RIPK1 (0.53) RIPK1
SCHEMBL20166581 0.77 RIPK1 (0.51) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062735-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-27 US disclosed
US-20190345138-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 US disclosed
EP-3541813-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-09-25 EP disclosed
WO-2018154520-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-08-30 WO disclosed
WO-2018092089-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-24 WO disclosed
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345138-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 RIPK1 440/4885TACR3 2029/4885PARP1 999/4885
US-20200062735-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS RIPK1, RIPK4, RIPK3 RIPK1 1/4885TACR3 4153/4885PARP1 154/4885
US-20160194349-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION TEK, PLIN3, FABP3 RIPK1 1983/4885TACR3 3736/4885PARP1 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.